Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $107.00 Average Target Price from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus recommendation of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $107.00.

A number of analysts have weighed in on the company. Morgan Stanley assumed coverage on Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, January 29th. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MNPR. Wellington Management Group LLP purchased a new position in shares of Monopar Therapeutics in the 3rd quarter valued at $18,904,000. Siren L.L.C. purchased a new stake in Monopar Therapeutics in the fourth quarter valued at $13,863,000. Deerfield Management Company L.P. acquired a new position in Monopar Therapeutics in the third quarter valued at $13,048,000. RA Capital Management L.P. boosted its stake in Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after acquiring an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics during the third quarter worth about $12,496,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Trading Down 0.8%

Shares of NASDAQ:MNPR opened at $54.10 on Wednesday. Monopar Therapeutics has a 52 week low of $26.06 and a 52 week high of $105.00. The company’s 50 day moving average is $59.62 and its two-hundred day moving average is $70.57. The company has a market cap of $361.39 million, a PE ratio of -15.73 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, equities research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.